Immunotherapy of HCC

被引：50

作者：

Greten, Tim F. ^{[1
]}

Manns, Michael P. ^{[1
]}

Korangy, Firouzeh ^{[1
]}

机构：

[1] Med Sch Hannover, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany

来源：

REVIEWS ON RECENT CLINICAL TRIALS | 2008年 / 3卷 / 01期

关键词：

D O I：

10.2174/157488708783330549

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with increasing incidence in the Western World. In contrast to most other malignancies, only surgical and local ablative therapeutic options have shown efficacy in patients with HCC. Systemic chemotherapy has failed to show a substantial benefit for these patients. Therefore, a number of immunotherapeutic trials have been performed to evaluate the efficacy of immunotherapy for the treatment of HCC. Although only a limited number of patients have been enrolled in most trials so far, results from these studies clearly suggest that immunotherapy is safe in HCC patients. Here, we review recent immunotherapy trials in HCC.

引用

页码：31 / 39

页数：9

共 113 条

[1] LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY IN ASSOCIATION WITH THE PINEAL HORMONE MELATONIN AS A FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR-CARCINOMA [J].

ALDEGHI, R ;

LISSONI, P ;

BARNI, S ;

ARDIZZOIA, A ;

TANCINI, G ;

PIPERNO, A ;

POZZI, M ;

RICCI, G ;

CONTI, A ;

MAESTRONI, GJM .

EUROPEAN JOURNAL OF CANCER, 1994, 30A (02) :167-170

[2] Activation of dendritic cells by local ablation of hepatocellular carcinoma [J].

Ali, MY ;

Grimm, CF ;

Ritter, M ;

Mohr, L ;

Allgaier, HP ;

Weth, R ;

Bocher, WO ;

Endrulat, K ;

Blum, HE ;

Geissler, M .

JOURNAL OF HEPATOLOGY, 2005, 43 (05) :817-822

[3]

[Anonymous], 1990, Cancer, V66, P135

[4] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[5] Unmasking of α-fetoprotein-specific CD4+ T cell responses in hepatocellular carcinoma patients undergoing embolization [J].

Ayaru, Lakshmana ;

Pereira, Stephen P. ;

Alisa, Akeel ;

Pathan, Ansar A. ;

Williams, Roger ;

Davidson, Brian ;

Burroughs, Andrew K. ;

Meyer, Tim ;

Behboudi, Shahriar .

JOURNAL OF IMMUNOLOGY, 2007, 178 (03) :1914-1922

[6] Local/regional and systemic treatments of hepatocellular carcinoma [J].

Beaugrand, M ;

N'kontchou, G ;

Seror, O ;

Ganne, N ;

Trinchet, JC .

SEMINARS IN LIVER DISEASE, 2005, 25 (02) :201-211

[7] Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets [J].

Beckebaum, S ;

Zhang, X ;

Chen, X ;

Yu, ZY ;

Frilling, A ;

Dworacki, G ;

Grosse-Wilde, H ;

Broelsch, CE ;

Gerken, G ;

Cicinnati, VR .

CLINICAL CANCER RESEARCH, 2004, 10 (21) :7260-7269

[8] NO SYNERGISTIC ACTIVITY OF EPIRUBICIN AND INTERFERON-ALPHA-2B IN THE TREATMENT OF HEPATOCELLULAR-CARCINOMA [J].

BOKEMEYER, C ;

KYNAST, B ;

HARSTRICK, A ;

LAAGE, E ;

SCHMOLL, E ;

VONWUSSOW, P ;

SCHMOLL, HJ .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (04) :334-338

[9] Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma [J].

Bricard, G ;

Bouzourene, H ;

Martinet, O ;

Rimoldi, D ;

Halkic, N ;

Gillet, M ;

Chaubert, P ;

MacDonald, HR ;

Romero, P ;

Cerottini, JC ;

Speiser, DE .

JOURNAL OF IMMUNOLOGY, 2005, 174 (03) :1709-1716

[10] Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].

Bruix, J ;

Sherman, M ;

Llovet, JM ;

Beaugrand, M ;

Lencioni, R ;

Burroughs, AK ;

Christensen, E ;

Pagliaro, L ;

Colombo, M ;

Rodés, J .

JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430

← 1 2 3 4 5 6 7 8 9 10 →